STOCK TITAN

Adlai Nortye (ANL) Schedule 13G/A: Director‑linked entities report 4.56M shares

(Neutral)
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Adlai Nortye Ltd. files a Schedule 13G/A reporting beneficial ownership of 4,561,077 ordinary shares. The filing states this holding represents 2.9% of the issuer's ordinary shares based on April 10, 2026 outstanding counts. The calculation references 142,241,572 Class A and 16,990,000 Class B ordinary shares outstanding as of that date, and attributes sole voting and dispositive power over the 4,561,077 shares to JIN YIN (BVI) LIMITED with a chain of indirect ownership through related entities and Shijun Feng.

Positive

  • None.

Negative

  • None.

Insights

Filing documents a passive beneficial ownership stake of 2.9% held through related entities.

The statement lists 4,561,077 shares under the sole voting and dispositive power of JIN YIN (BVI) LIMITED, with ownership traced through Shanghai Gaopei Duwei Biotechnology Co., Ltd., Hangzhou Jingyin Investment Partnership, Hangzhou Jingfeng Investment Management Company, and ultimately to Shijun Feng. The cover comments tie the percentage to the issuer's reported outstanding share counts as of April 10, 2026.

Filing certifies the holdings were not acquired to influence control; cash‑flow treatment is not stated. Subsequent filings may disclose changes in position or voting arrangements.

Schedule 13G/A structure and attribution appear consistent with passive reporting and group beneficial-ownership rules.

The filing identifies the direct holder and describes the ownership chain that may cause attribution to affiliates and to Shijun Feng. It includes a signed certification asserting the shares are not held to change control. The statement references specific outstanding share counts used for the 2.9% calculation.

Material compliance items to watch in future filings include any amendment converting this to an active Schedule 13D or changes in sole voting/dispositive power.

Reported shares beneficially owned 4,561,077 shares Sole voting/dispositive power attributed to JIN YIN (BVI) LIMITED
Reported ownership percentage 2.9% Calculated using outstanding shares as of April 10, 2026
Class A outstanding 142,241,572 shares As of April 10, 2026
Class B outstanding 16,990,000 shares As of April 10, 2026
beneficially owned regulatory
"Representing 4,561,077 Class A ordinary shares of the Issuer held by JIN YIN (BVI) LIMITED"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
sole dispositive power regulatory
"Sole Dispositive Power 4,561,077.00"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.
Schedule 13G/A regulatory
"Item 1. Name of issuer: Adlai Nortye Ltd."
A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What stake does ANL Schedule 13G/A report for JIN YIN (BVI) LIMITED?

The filing reports 4,561,077 shares, representing 2.9% of the issuer's ordinary shares using the outstanding counts as of April 10, 2026.

How was the 2.9% ownership percentage calculated in the ANL filing?

The percentage is based on 142,241,572 Class A and 16,990,000 Class B ordinary shares outstanding as of April 10, 2026, as cited in the filing.

Who holds voting and dispositive power over the reported ANL shares?

The filing states JIN YIN (BVI) LIMITED has sole voting and sole dispositive power over the 4,561,077 shares reported on the cover pages.

Does the Schedule 13G/A indicate an intent to influence control of ANL?

No. The certifications state the securities "were not acquired and are not held for the purpose of or with the effect of changing or influencing the control" of the issuer.

Which entities are in the ownership chain for the ANL holdings?

The filing lists an ownership chain: JIN YIN (BVI) LIMITED owned by Shanghai Gaopei Duwei Biotechnology Co., Ltd., linked to Hangzhou Jingyin Investment Partnership, Hangzhou Jingfeng Investment Management Company, and ultimately Shijun Feng.





00704R109

(CUSIP Number)
12/31/2023

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: (1) Representing 4,561,077 Class A ordinary shares of the Issuer held by JIN YIN (BVI) LIMITED. (2) This percentage is calculated based on a total of (i) 142,241,572 Class A ordinary shares and 16,990,000 Class B ordinary shares outstanding of the Issuer as of April 10th, 2026 as reported in the Issuer's annual report on Form 20-F filed on the same date.


SCHEDULE 13G




Comment for Type of Reporting Person: (3) Representing 4,561,077 Class A ordinary shares of the Issuer held by JIN YIN (BVI) LIMITED. Shanghai Gaopei Duwei Biotechnology Co., Ltd. holds 100.0% equity interest of JIN YIN (BVI) LIMITED.


SCHEDULE 13G




Comment for Type of Reporting Person: (4) Representing 4,561,077 Class A ordinary shares of the Issuer held by JIN YIN (BVI) LIMITED. Shanghai Gaopei Duwei Biotechnology Co., Ltd. holds 100.0% equity interest of JIN YIN (BVI) LIMITED. Hangzhou Jingyin Investment Partnership (Limited Partnership) holds 99.0% equity interest of Shanghai Gaopei Duwei Biotechnology Co., Ltd.


SCHEDULE 13G




Comment for Type of Reporting Person: (5) Representing 4,561,077 Class A ordinary shares of the Issuer held by JIN YIN (BVI) LIMITED. Shanghai Gaopei Duwei Biotechnology Co., Ltd. holds 100.0% equity interest of JIN YIN (BVI) LIMITED. Shanghai Gaopei Duwei Biotechnology Co., Ltd. holds 100.0% equity interest of JIN YIN (BVI) LIMITED. Hangzhou Jingyin Investment Partnership (Limited Partnership) holds 99.0% equity interest of Shanghai Gaopei Duwei Biotechnology Co., Ltd. Hangzhou Jingfeng Investment Management Company is the general partner of Hangzhou Jingyin Investment Partnership (Limited Partnership), and may be deemed to beneficially own the ordinary shares beneficially owned by Hangzhou Jingyin Investment Partnership (Limited Partnership).


SCHEDULE 13G




Comment for Type of Reporting Person: (6) Representing 4,561,077 Class A ordinary shares of the Issuer held by JIN YIN (BVI) LIMITED. Shanghai Gaopei Duwei Biotechnology Co., Ltd. holds 100.0% equity interest of JIN YIN (BVI) LIMITED. Shanghai Gaopei Duwei Biotechnology Co., Ltd. holds 100.0% equity interest of JIN YIN (BVI) LIMITED. Hangzhou Jingyin Investment Partnership (Limited Partnership) holds 99.0% equity interest of Shanghai Gaopei Duwei Biotechnology Co., Ltd. Hangzhou Jingfeng Investment Management Company is the general partner of Hangzhou Jingyin Investment Partnership (Limited Partnership), and may be deemed to beneficially own the ordinary shares beneficially owned by Hangzhou Jingyin Investment Partnership (Limited Partnership). Shijun Feng holds 100.0% equity interest of Hangzhou Jingfeng Investment Management Company.


SCHEDULE 13G



JIN YIN (BVI) LIMITED
Signature:/s/ Shijun Feng
Name/Title:Shijun Feng/Director
Date:05/14/2026
Shanghai Gaopei Duwei Biotechnology Co., Ltd.
Signature:/s/ Shijun Feng
Name/Title:Shijun Feng/Director
Date:05/14/2026
Hangzhou Jingyin Investment Partnership (Limited Partnership)
Signature:/s/ Yue'ai Jiang
Name/Title:Yue'ai Jiang/Authorized Person
Date:05/14/2026
Hangzhou Jingfeng Investment Management Company
Signature:/s/ Shijun Feng
Name/Title:Shijun Feng/Director
Date:05/14/2026
Shijun Feng
Signature:/s/ Shijun Feng
Name/Title:Shijun Feng
Date:05/14/2026
Exhibit Information

99.1 Joint Filing Agreement